Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;34(5):433-438.
doi: 10.5114/ada.2017.71108. Epub 2017 Oct 31.

Pregnancy: a therapeutic dilemma

Affiliations

Pregnancy: a therapeutic dilemma

Ligia Brzezińska-Wcisło et al. Postepy Dermatol Alergol. 2017 Oct.

Abstract

Treatment during pregnancy is problematic. The Food and Drug Administration established drug categories to help in the treatment process. First-generation antihistamines are considered safe but they have sedative properties. Second-generation antihistamines cause less adverse reactions but besides cetirizine and loratadine they belong to category C. All retinoids should be avoided during pregnancy due to the risk of fetal malformations. Antimalarial drugs should be considered based on the clinical data. Sulfones can be considered as safe for use during pregnancy only with proper monitoring. Prednisone is administered in pregnancy. Other glucocorticosteroids have a different safety profile. Cyclosporine A treatment should be reserved as rescue therapy in severe stages of the disease. Treatment during pregnancy should be precise when it comes to pregnant woman and safe for the fetus.

Keywords: antihistamine; antimalarial drugs; drug categories; pregnancy; retinoids.

PubMed Disclaimer

Similar articles

References

    1. Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother. 2012;3:105–8. - PMC - PubMed
    1. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203. - PubMed
    1. Lis-Swiety A, Brzezinska-Wcislo L. The safety of the antihistamines in dermatoses of pregnancy. Wiad Lek. 2006;59:89–91. - PubMed
    1. Meadows M. Pregnancy and the drug dilemma. FDA Consum. 2001;35:16–20. - PubMed
    1. Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy reply letter. J Am Acad Dermatol. 2014;70:1136–7. - PubMed

LinkOut - more resources